19 November 2018
\n \n \n \nBertil Damato will oversee the provision of clinical care to patients with an ocular tumour and develop a research group to focus on ocular melanoma and other eye tumours.
\n \n\n \n \n8 October 2018
\n \n \n \nThe positive results of the world\u2019s first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in this week\u2019s edition of Nature Medicine.
\n \n\n \n \n30 September 2018
\n \n \n \nMillions of people are to be given access to digital treatment for insomnia as an alternative to sleeping pills. Study by Colin Espie et al shows that Sleepio improves wellbeing in nearly three quarters of participants.
\n \n\n \n \n18 June 2018
\n \n \n \nThe first trial of robot-assisted eye surgery in patients has shown the technique to be both safe and effective.
\n \n\n \n \n12 March 2018
\n \n \n \nResearchers at the Sleep and Circadian Neuroscience Institute (SCNi) have been working with visual artist Martin Kohout to reveal the stories of the night-shift workers who keep London running.
\n \n\n \n \n3 October 2017
\n \n \n \nIn a laboratory study in Oxford, researchers have shown how it might be possible to reverse blindness using gene therapy to reprogram cells at the back of the eye to become light sensitive.
\n \n\n \n \n8 September 2017
\n \n \n \n\n \n \n20 March 2017
\n \n \n \nResearchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people.
\n \n\n \n \n3 January 2017
\n \n \n \nCircadian Therapeutics has been established to identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.
\n \n\n \n \n10 November 2016
\n \n \n \nThe trial involves injecting a virus into the eye to deliver billions of healthy genes to replace a key missing gene for choroideremia sufferers.
\n \n\n \n \n13 September 2016
\n \n \n \nUniversity of Oxford surgeons at Oxford's John Radcliffe Hospital have performed the world's first operation inside the eye using a robot.
\n \n\n \n \n9 August 2016
\n \n \n \nA spinout company from our Department, OxSight, has reported that in a recent UK-wide trial its smart glasses helped sight impaired and blind people to navigate independently, avoid collisions and see in the dark.
\n \n\n \n \n15 June 2016
\n \n \n \nOur researchers have shown how different colours of light could affect our ability to sleep.
\n \n\n \n \n29 April 2016
\n \n \n \nPioneering gene therapy has restored some vision to John Radcliffe Hospital patients with a rare form of genetic blindness for as long as four years, raising hopes it could be used to cure common causes of vision loss, new University of Oxford research published today shows.
\n \n\n \n \n31 March 2016
\n \n \n \nExperts call for introduction of sleep guidelines in new report
\n \n\n \n \n2 March 2016
\n \n \n \n\n \n \n5 January 2016
\n \n \n \nA patient who is the first in the UK to receive the world\u2019s most advanced 'bionic eye' has been able to read the time for the first time in more than five years.
\n \n\n \n \n10 November 2015
\n \n \n \nProfessor Russell Foster writes about circadian rhythm and health on the online news platform 'The Conversation'
\n \n\n \n \n9 November 2015
\n \n \n \nMore money comes in to further work on gene therapy for choroideremia
\n \n\n \n \n9 November 2015
\n \n \n \nFind out a bit about our research into circadian rhythms
\n \n\n \n \n